Skip to main content
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, &

Dr. John Cush RheumNow

1 year 3 months ago
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/GhLtLqT0iS
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcome

Dr. John Cush RheumNow

1 year 3 months ago
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not https://t.co/VrLfiSGWGA
Vitamin D for Prevention of Disease

JAMA has published a clinical guideline on the use of vitamin D to prevent disease

Dr. John Cush RheumNow

1 year 3 months ago
Vitamin D for Prevention of Disease JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults. Guideline committee experts, included adult and pediatric endocrinology, internal medicine, obstetrics/gynecology, nutrition, and https://t.co/zi3CpE0DVN
Metformin Effective in Osteoarthritis
  • MedPage Today
The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.
A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs who care for FMF patients.
Simplistic overview of Lupus Nephritis - causes, risk factors, symptoms, diagnosis, and treatment of lupus nephritis. ht

Dr. John Cush RheumNow

1 year 3 months ago
Simplistic overview of Lupus Nephritis - causes, risk factors, symptoms, diagnosis, and treatment of lupus nephritis. https://t.co/QkLXUQcSqo https://t.co/pGjCHmoelG
Unmet Needs in Still’s disease

In February 2023, an expert consensus panel of pediatric and adult rheumatologists me

Dr. John Cush RheumNow

1 year 3 months ago
Unmet Needs in Still’s disease In February 2023, an expert consensus panel of pediatric and adult rheumatologists met to address challenges in Still’s disease (SD), including systemic juvenile idiopathic arthritis (sJIA) and adult-onset SD (AOSD). They addressed four main https://t.co/h6FNkQyoKj
2025 BSR Guideline for Treatment of Axial Spondyloarthritis

The British Society of Rheumatology has published its 2025

Dr. John Cush RheumNow

1 year 3 months ago
2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology has published its 2025 Guidelines for the Treatment of Axial Spondyloarthritis (axSpA); addressing axial and extra-musculoskeletal manifestations including acute anterior uveitis, https://t.co/IRdxsZTFdC
“Always laugh when you can. It is cheap medicine."
– Lord Byron https://t.co/SWfnTPEJs0

Dr. John Cush RheumNow

1 year 3 months ago
“Always laugh when you can. It is cheap medicine." – Lord Byron https://t.co/SWfnTPEJs0
Better Responses with Chronotherapy for Baricitinib

A nonrandomized, open-label, controlled trial has shown superior e

Dr. John Cush RheumNow

1 year 3 months ago
Better Responses with Chronotherapy for Baricitinib A nonrandomized, open-label, controlled trial has shown superior efficacy when baricitinib was given at night (instead of day); attesting to the benefits of chronotherapy - selective dosing meant to target the body's diurnal https://t.co/jSrPdoOpmo
Post-treatment Lyme Syndrome

Symptoms that persist long after Lyme disease is treated are not uncommon — a 2022 stud

Dr. John Cush RheumNow

1 year 3 months ago
Post-treatment Lyme Syndrome Symptoms that persist long after Lyme disease is treated are not uncommon — a 2022 study found that 14% of patients who were diagnosed and treated early with antibiotic therapy would still develop Post Treatment Lyme Disease (PTLD). https://t.co/mmwGCnARY8
Senescent "Zombie" Cells and Low Back Pain

In a preclinical study led by McGill University researchers, two drugs targ

Dr. John Cush RheumNow

1 year 3 months ago
Senescent "Zombie" Cells and Low Back Pain In a preclinical study led by McGill University researchers, two drugs targeting “zombie cells” have been shown to treat the underlying cause of chronic low back pain. The condition affects millions of people worldwide. https://t.co/UxHH3bMGkQ
Diabetes Prevention with Hydroxychloroquine in Sjogren’s

A Taiwanese insurance claims analysis looked at HCQ use in

Dr. John Cush RheumNow

1 year 3 months ago
Diabetes Prevention with Hydroxychloroquine in Sjogren’s A Taiwanese insurance claims analysis looked at HCQ use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of https://t.co/GS07GVp5pC
🦋 This May, RheumNow brings you Lupus Unlocked – Keys to Mastery
Your one-stop hub for lupus education:
✅ Expert

Dr. John Cush RheumNow

1 year 3 months ago
🦋 This May, RheumNow brings you Lupus Unlocked – Keys to Mastery Your one-stop hub for lupus education: ✅ Expert KOL content ✅ Weekly webinars & podcasts ✅ Engaging surveys + slides Sponsored by Aurinia — empowering HCPs to advance care. #Lupus #Rheumatology https://t.co/rf4GveV3eh
Metanalysis suggests MTX may be effective in knee OA. 6RCTs, 602 pts of MTX vs PBO, showed MTX significantly relieved pa

Dr. John Cush RheumNow

1 year 3 months ago
Metanalysis suggests MTX may be effective in knee OA. 6RCTs, 602 pts of MTX vs PBO, showed MTX significantly relieved pain (mean diff −0.44; P 0.0003) knee/hand OA; Functional improved for knee only, but no differences in quality-of-life outcome or adverse events https://t.co/lmBEnTLFHY
×